Cambridge Investment Research Advisors
ONCY

Cambridge Investment Research Advisors’s Oncolytics Biotech ONCY Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Hold
10,771
– – ﹤0.01% 4033
2026
Q1 		$9K Buy
+10,771
New +$10.7K ﹤0.01% 3911
2025
Q4 		– Sell
-24,771
Closed -$35K – 3919
2025
Q3 		$35K Buy
24,771
+13,500
+120% +$15.1K ﹤0.01% 3670
2025
Q2 		$9K Buy
+11,271
New +$5.97K ﹤0.01% 3597

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.71B AUM 30.33% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAS
Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Cambridge Investment Research Advisors's ONCY Position: Q2 2026 in Review

Cambridge Investment Research Advisors held its Oncolytics Biotech (ONCY) position steady in Q2 2026 at 10,771 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #4033.

Cambridge Investment Research Advisors first reported a position in ONCY in Q2 2025 and has held it in 4 quarters since. The position peaked at $35K in Q3 2025. 24 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Cambridge Investment Research Advisors held 10,771 shares of Oncolytics Biotech worth $10K as of Q2 2026.
  • Cambridge Investment Research Advisors left its Oncolytics Biotech share count unchanged in Q2 2026.
  • Oncolytics Biotech made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #4033 holding.
  • Cambridge Investment Research Advisors first reported a position in Oncolytics Biotech in Q2 2025 and has held it in 4 quarters since.
  • Cambridge Investment Research Advisors's Oncolytics Biotech position peaked at $35K in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.